Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine-CHOP for Nodal T-cell Lymphoma with TFH Phenotype
NCT05230680Phase 2Recruiting
- Start
- Jul 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL) and follicular T-cell lymphoma (FTCL). Primary endpoint: Complete Response Rate at 72 months. Started Jul 2022; status: recruiting.
02
Drugs
azacitidine
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)follicular T-cell lymphoma (FTCL)
Beyond the preview
Go deeper on NCT05230680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05230680.